Your Voice is Important
The End Brain Cancer Initiative wants to make your voice heard. By participating in one of the studies below, you will advance our understanding of the treatment and management of these diseases.
Metastatic Non-Small Cell Lung Cancer (NSCLC) Survey
People diagnosed within the last three years with Non-Small Cell Lung Cancer (NSCLC) that has metastasized to the brain are invited to participate in this paid opportunity.
- Receive $200 for your time
- 10-15 minute surveys for up to 2 weeks
- 60 minutes total of tasks
Low Grade Glioma (LGG) Patient Survey
Low Grade Glioma (LGG) patients are invited to take a short anonymous online survey. Responses will be used to build programs to better serve Low Grade Glioma patients and their families.
- 15-minute online survey
- For LGG patients & caregivers
- Patients must be 18+ years old
Recurrent Glioblastoma (rGBM) Study
Your perspectives and insights will help to shape future treatments for GBM!
Call 425.436.8688 or click below.
Understanding newly diagnosed, first recurrent, and recurrent in GBM
Newly Diagnosed GBM
Signifies the initial diagnosis of glioblastoma multiforme. It occurs when a patient experiences symptoms like headaches, seizures, vision problems, and seeks medical attention. During a routine check-up or through MRI and CT scans, a sizable brain mass or tumor is detected. Subsequent medical tests confirm the diagnosis of GBM.
Recurrent GBM
As its name suggests, indicates the return of the cancerous tumor. This recurrence becomes apparent through a follow-up set of MRI or CT scans. Recurrent GBM implies that, despite previous interventions such as surgery, chemotherapy, and radiation, the tumor has proven resilient and reappeared in the same area of the brain.
First Recurrent GBM
Specifies that after the initial diagnosis and the treatments administered to eliminate cancer cells, this marks the first instance of recurrence or reappearance.
This PRO rGBM survey is only for patients with first recurrent GBM.
Now offering evening availability!
To better accommodate working participants and those in different time zones, our Clinical Research Coordinator/Patient Navigator is now available two evenings a week to conduct rGBM Study interviews: Tuesdays and Wednesdays from 6PM to 9PM PST.
Questions? Contact Shreya Prakash:
425-436-8688
shreya@endbraincancer.org
